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Summary: The HPLC method for the simultaneous determination of urinary neopterin, pseudouridine, and
creatinine allows a rapid evaluation of the activation state of cell-mediated immunity, and the stimulation of
whole-body rRNA + tRNA turnover, associated with malignant growth ..Urinary neopterin and pseudouridine
concentrations in healthy subjects amounted to: 106.6 ± 34.6 μιηοΐ/mol creatinine, and 19.6 ± 5.2 mmol/mol
creatinine (x ± SD), respectively. The increase of neopterin excretion in patients with haematological neo-
plasms ranged from 146% in Hodgkitfs disease to 534% in non-Hodgkin's lymphoma, whereas the increase
in cancer cases ranged from 95% in adenocarcinoma of the gaster to 741% in hepatocellular carcinoma. The
changes in pseudouridine excretion were much less pronounced: 63% in non-ffodgkin's lymphoma and 120%
in carcinoma of the urinary bladder. The correlation coefficient between neopterin and pseudouridine was
relatively low (r = 0.43), although statistically significant (P < 0.01). In the case of several neoplasms e.g.
Hodgkin's disease, polycythaemia vera, and adenocarcinoma of the gaster, neopterin was significantly elevated,
whereas pseudouridine remained at a normal concentration. There was a positive relationship between the
stage of the disease (primary focus, regional metastases, dissemination) and urinary concentration of pseu-
douridine in patients with adenocarcinoma of the large intestine. In the same patients the increase of neopterin
excretion was noticed both in early and advanced stages, with the highest values in disseminated disease.
Introduction . , m ι i_ ,^ ~™ - Λactivated T-lymphocytes (1). Thus, neopterin deter-
Neopterin and pseudouridine detected in biological mined in blood serum (2) and urine (3) is considered
fluids are used as biochemical markers of malignancy, as a good marker of T-cell activation. A significant
but the source and mechanism of their elevation are diurnal rhythm of neopterin in urine has been detected
different. Determination of neopterin in blood plasma with a peak at 06.30 h (4). Hausen et al. (5) has
and urine provides information about the activation reviewed malignant diseases associated with increased
state of cell-mediated immunity in vivo. Neopterin is urinary and/or serum neopterin concentrations: hae-
synthesized from guanosine triphosphate by macro- matological neoplasms, gynaecological tumours, tum-
phages by the action of GTP cyclohydrolase, an en- ours of the genitourinary tract, lung cancer, gastro-
zyme induced by interferon gamma and derived from intestinal and pancratic carcinoma, melanomas,
_ breast tumours, head and neck cancers.
* Nado'naf ̂  Wttod by a gnmt from the Miniitry of The source of pseudouridine excreted in urine is
** Submitted March 30/August 31, 1992 to "Pteridines" which whole-body catabolism of tRNA and rRNA (6). Pseu-
discontinued with vol. 3, no. 3, 1992. douridine is not re-utilized in nucleotide synthesis by
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the salvage pathway, appears in blood plasma, and is
quantitatively excreted in urine (7). Pseudouridine is
generally excreted in concentrations of 10 to 100 times
those of other nucleosides, both in healthy subjects
and cancer patients (8, 9). There is a considerable
number of publications concerning changes in urinary
pseudouridine excretion evoked by malignant growth
(9-15).
The present work was carried out to compare urinary
neopterin and pseudouridine excretion in patients
with haematological proliferative diseases and cancer.
We offer a simple, sensitive and rapid HPLC method
for the simultaneous determination of neopterin,




Observations were performed on 130 individuals. The control
group consisted of 31 healthy volunteers aged between 20 and
70 years.
The group with haematological neoplasms consisted of
52 patients:
15 with chronic lymphocytic leukaemia,
7 with multiple myeloma,
12 with other non-Hodgkirfs lymphomas,
4 with myelofibrosis,
4 with Hodgkin's disease,
4 with chronic granulocytic leukaemia.
The group with cancer consisted of
47 patients:
7 with carcinoma of the lung,
10 of the rectum,
7 of the colon,
6 of the pancreas,
4 of the gaster,
3 of the liver (hepatoceliular),
4 of the urinary bladder,
3 of the kidney,
3 of the testis.
Urine collection and preparation
The first morning urine of healthy individuals and patients with
Chromatographie method
High performance liquid chromatography (HPLC) was per-
formed with an isocratic liquid Chromatograph Beckman 330
using an ultrasphere Altex column Op.S 5 μπι, 4.6 χ 250 mm,
RP-18 cartridge precolumn (4.6 χ 30 mm), and RP-18 guard
cartridge (3.2 χ 15 mm) — Pierce. The absorbance of pseu-
douridine and creatinine was measured by UV detector Beck-
man 153 equipped with a 254 nm filter. Effluent was then passed
through a Shimadzu RF-535 fluorescence detector where neo-
pterin was detected by its native fluorescence. Each detector









malignant proliferative diseases was stored at -20 °C in the Fig. 1. HPLC chromatogram.
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dark prior to the analysis. Samples of urine were prepurified
using Sep-Pak Ci8 cartridges (Waters Assoc.). To protect neo-
pterin from photooxidation, sample preparation was performed
in dim light.
UV detection (upper): 3.73 rain - orotic acid, 4.44 min
— uric acid, 5.73 min — creatinine, 7.28 min — pseu-
douridine.
Fluorescence detection (lower): 8.46 min - neopterin.
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The mobile phase was 0.01 mol/1 potassium dihydrogen phos-
phate (pH 5.9) containing methanol, volume fraction 0.01, at
a flow rate of 1 ml χ min""1. Samples were injected through an
autosampler Spark-Holland 125 Fix equipped with dark glass
vials and a 20 μΐ loop. An example of a urine HPLC chromato-
gram is presented in figure 1.
Statistical analysis
Results were statistically evaluated by ANOVA and Tukey range
test (the significance of differences between the means of each
group and subgroup of patients), and Studenfs t-test (the sig-
nificance of differences between control group and each group
of tumour patients). Correlation coefficients were calculated by
the method of least squares. The probability of differences
between averages at the level Ρ < 0.05 was taken as significant,
and at the level Ρ ̂  0.01 as highly significant.
Results and Discussion
The HPLC method for the simultaneous determina-
tion of urinary neopterin, pseudouridine and creati-
nine (fig. 1) allows the rapid evaluation of the acti-
vation state of cell-mediated immunity and the rate
of whole-body rRNA + tRNA turnover, associated
with malignant growth. The values of urinary neop-
terin and pseudouridine concentrations in healthy
subjects (106.6 ± 34.6 μπιοΐ/mol creatinine, and 19.5
± 7.6 mmol/mol creatinine, respectively) are com-
parable to those described in earlier reports (4, 6).
Among haematological proliferative diseases, the
highest increases (P < 0.01) of both analyses were
observed in non^-Hodgkin's lymphoma (neopterin:
675.7 μιηοΐ/mol creatinine; pseudouridine: 31.8 mmol/
mql creatinine), chronic lymphocytic leukaemia
(neopterin: 438.4 μιηοΐ/mol creatinine, pseudouridine:
29.5 mmol/mol creatinine), myelofibrosis, and multi-
ple myeloma (fig. 2).
The increase of urinary neopterin excretion was evi-
dent (P < 0.01) in all examined cases of cancer (fig.
2) with the highest values in hepatocellular carcinoma
(897.0 μπιοΐ/mol creatinine), adenocarcinoma of the
pancreas (632.7 nml/mmol creatinine), adenocarci-
noma of the rectum (609.1 μιηοΐ/mol creatinine), and
adenocarcinoma of the colon (566.8 μιηοΐ/mol creat-
inine). The highest concentrations of urinary pseu-
douridine were observed in carcinoma of the urinary
bladder (42.8 mmol/mol creatinine), and hepatocel-
lular carcinoma (37.5 mmol/mol creatinine).
Generally, the changes of urinary neopterin and pseu-
douridine excretion showed a similar trend, but not
in all examined patients. This reflected in a relatively
low, although statistically significant, correlation co-
efficient (r = 0.43, P < 0.01) between urinary neo-






























Fig. 2. The average urinary neopterin and pseudouridine concentration in patients with haematological proliferative diseases and
cancers.
* values significantly (P < 0.05) different from the control;
** values highly significantly (Ρ ̂  0.01) different from the control.
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plasms, e. g. Hodgkin's disease, polycythaemia vera,
and adenocarcinoma of the gaster, neopterin was sig-
nificantly elevated, whereas pseudouridine remained
at a normal concentration. This confirms our findings
of a poor response of blood plasma pseudouridine in
the mentioned diseases (unpublished data). It should
also be noted that elevations in urinary neopterin are
much more pronounced than those of pseudouridine,
both in haematological neoplasms and examined can^
cers (fig. 2). The increase (expressed as % increase)
of neopterin excretion in haematological proliferative
diseases ranged from 146% in Hodgkin's disease to
534% in non-Hodgkin's lymphoma, whereas the high-
est increase of pseudouridine excretion in non-Hodg-
kin's lymphoma was 62%. Similarly, in cancer pa-
tients, the increase of neopterin excretion ranged from
95% in adenocarcinoma of the gaster to 741% in
hepatocellular carcinoma, but the maximal increase
of pseudouricline excretion of 120% was observed in
carcinoma of the urinary bladder. This is also illus-
trated by figure 3, where urinary excretion of neo-
pterin and pseudouridine is presented in relation to
the stage of adenocarcinoma of the large intestine. If
the particular stages described as primary focus, re-
gional metastases, and dissemination are assigned hy-
pothetical values of 1, 2 and 4, respectively, the rela-
tionship between the stage and urinary pseudouridine
excretion is statistically significant (r = 0.60,
P < 0.01). It reflects the progressive increase of rRNA
+ tRNA turnover, associated with tumour burden.
There was no such relationship between the stage of
the disease and urinary neopterin, which was elevated
both in early and advanced stages of malignant
growth (fig. 3). It seems important that both markers
provide to some extent independent information
about malignant growth (pseudouridine) and immune
activation (neopterin) in the same patient. The lack
of correlation between the changes observed in pseu-
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Fig. 3. The relationship between the stage of disease and uri-
nary neopterin (closed circles) and pseudouridine (open
circles) concentration in patients with adenocarcinoma
of the large intestine.
could mean that not only malignant growth but also
other influences e. g. degree of cell differentiation, are
important in the induction of immune activation in
patients.
In conclusion, urinary neopterin is a more sensitive
biochemical marker of malignancy than pseudouri-
dine. Simultaneous determination of neopterin, pseu-
douridine, and creatinine by HPLC is a simple, rapid,
precise, and relatively inexpensive method, which can
be useful in many medical laboratories.
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